NCT01131325View on ClinicalTrials.gov

Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations

PHASE4TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

October 21, 2010

Primary Completion Date

May 12, 2011

Study Completion Date

May 12, 2011

Conditions
CMLPhiladelphia Chromosome Positive (Ph+)Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough Levels
Interventions
DRUG

nilotinib

All patients will receive nilotinib 300mg bid po daily. Nilotinib dose is taken every 12 hours

Trial Locations (3)

75246

Baylor Health Care System/Sammons Cancer Center Dept. of Sammons Cancer (2), Dallas

79106

Cancer Center of the High Plains, Amarillo

89109

Comprehensive Cancer Centers of Nevada CCC of Nevada (1), Las Vegas

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY